Sunvozertinib

Tier C — Watch / trade

Sunvozertinib

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：EGFR exon 20 insertion mutations, EGFR L858R, EGFR T790M, HER2 exon 20 insert mutations

Brand：ZEGFROVY

Indications (approved)：Non-small cell lung cancer

Regional status

Approved

2025-07-02

Phase III

2022-12-13

China

Approved

2023-08-22

Japan

Phase II

2019-07-09

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 6 · Total yield /

(I)1058685-1-a104901-79-3(II)1058685-1-a75-16-1(III)1058685-1-a2370014-05-2(IV)1058685-1-a3934-20-1(V)1058685-1-a—(VI)1058685-1-a1075705-01-9(VII)1058685-1-a—(VIIIa)1058685-1-a132958-72-6(VIIIb)1058685-1-a1246383-56-1(IX)1058685-1-a—(X)1058685-1-a—(XI)1058685-1-a814-68-6(XII)1058685-1-a625-36-5(XIII)1058685-1-a—API · Sunvozertinib

Code	CAS No.	Intermediate
(I)1058685-1-a	104901-79-3	Methyl 2-amino-4-chloro-5-fluorobenzoate
(II)1058685-1-a	75-16-1 Available	Bromo(methyl)magnesium
(III)1058685-1-a	2370014-05-2	2-(2-Amino-4-chloro-5-fluorophenyl)propan-2-ol
(IV)1058685-1-a	3934-20-1 Available	2-Chloropyrimidin-4-yl chloride
(V)1058685-1-a	-	2-[4-Chloro-2-[(2-chloropyrimidin-4-yl)amino]-5-fluorophenyl]propan-2-ol
(VI)1058685-1-a	1075705-01-9 Available	2-Amino-5-fluoro-4-nitroanisole
(VII)1058685-1-a	-	2-(4-Chloro-5-fluoro-2-[[2-(4-fluoro-2-methoxy-5-nitroanilino)pyrimidin-4-yl]amino]phenyl)propan-2-ol
(VIIIa)1058685-1-a	132958-72-6	(3R)-N,N-Dimethylpyrrolidin-3-amine
(VIIIb)1058685-1-a	1246383-56-1	(3R)-N,N-Dimethylpyrrolidin-3-amine hydrogen chloride (1/1)
(IX)1058685-1-a	-	2-[4-Chloro-2-[(2-[4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxy-5-nitroanilino]pyrimidin-4-yl)amino]-5-fluorophenyl]propan-2-ol
(X)1058685-1-a	-	2-[2-[(2-[5-Amino-4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl)amino]-4-chloro-5-fluorophenyl]propan-2-ol
(XI)1058685-1-a	814-68-6 Available	2-Propenoyl chloride
(XII)1058685-1-a	625-36-5 Available	(Chloromethyl)acetyl chloride
(XIII)1058685-1-a	-	3-Chloro-N-[5-([4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino)-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]propanamide

Frequently asked questions

What are the approved indications of Sunvozertinib?

Approved indications include: Non-small cell lung cancer.

When does the Sunvozertinib patent expire?

No public expiry year is available for Sunvozertinib yet; this page updates once verified.

How many synthesis routes are recorded for Sunvozertinib?

1 synthesis routes are recorded; the shortest is 6 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Sunvozertinib intermediates?

5 intermediate CAS of Sunvozertinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Sunvozertinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22